MESO · Mesoblast Ltd ADR
United States · RS rating 53 · As of 2026-11-03
| Price | 14.77 USD |
|---|---|
| 1-day change | +1.6% |
| RS rating (overall / 1M / 3M / 12M) | 53 / 68 / 64 / 42 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 27 / 12 / 23 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +29.5% |
| Market cap (USD) | $2.0B |